Mazabraud Yann sold $6.6M of RYTM
Mazabraud Yann (EVP, Head of International) sold 57,000 shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) at an average of $116.15 ($111.80–$117.47, $6.62M total) across 6 trades on 2026-08-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale may create minor short-term sentiment pressure, but the presence of a pre-arranged 10b5-1 plan generally limits interpretability as a negative fundamental signal.
Market read
Traders may monitor for follow-on insider activity, but the filing alone does not introduce new operational or financial information.
What to watch
The filing does not state tax, diversification, or compensation context; traders may overinterpret insider sales without those details.
Background
This is an SEC Form 4 insider transaction disclosure for Rhythm Pharmaceuticals, filed by an EVP responsible for international operations.
Ticker impact
RHYTHM PHARMACEUTICALS disclosed an EVP head of international open-market sale of 57,000 shares at a weighted average $116.1504.
Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around the filing date.
The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which reduces the signal strength versus discretionary selling. The article provides transaction size and pricing, but no new company fundamentals.
Market effects
No sector-wide read-through is provided; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity management under a 10b5-1 plan, implying little to no bearish information content.
Key entities
- issuerRHYTHM PHARMACEUTICALS, INC.
Company whose insider transaction was reported on Form 4.
- insiderMazabraud Yann
EVP, Head of International who sold 57,000 shares across six trades.
